<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000919</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 384</org_study_id>
    <secondary_id>11343</secondary_id>
    <secondary_id>AACTG A5005s</secondary_id>
    <secondary_id>AACTG A5006s</secondary_id>
    <secondary_id>AACTG A5007s</secondary_id>
    <secondary_id>AACTG A5031s</secondary_id>
    <secondary_id>AACTG 731</secondary_id>
    <nct_id>NCT00000919</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection</brief_title>
  <official_title>Study of Protease Inhibitor and/or Non-Nucleoside Reverse Transcriptase Inhibitor With Dual Nucleosides in Initial Therapy of HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effectiveness of various combinations of anti-HIV&#xD;
      drugs in HIV-positive men and women. Patients receive specific combinations of 3 or 4 of the&#xD;
      following 6 drugs: didanosine (ddI), stavudine (d4T) efavirenz (EFV), nelfinavir (NFV),&#xD;
      lamivudine (3TC), or zidovudine (ZDV).&#xD;
&#xD;
      Anti-HIV therapy is effective in preventing the spread of HIV in the body. However, patients&#xD;
      often experience unpleasant side effects and have difficulties following the dosing schedule.&#xD;
      This study looks for combinations of anti-HIV drugs (&quot;cocktails&quot;) which will be the most&#xD;
      effective with the fewest problems.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Highly active antiretroviral therapy, though effective in the suppression of HIV&#xD;
      proliferation, is often complicated by difficulties with adherence and drug toxicity. Various&#xD;
      combinations of highly active antiretroviral therapy exist; all have proved efficacious in&#xD;
      related trials. The question addressed in this trial is which combination of antiretroviral&#xD;
      &quot;cocktails&quot; provides the single greatest advantage in preventing the spread of HIV in the&#xD;
      body. In effect, which therapy provides the greatest benefit with the fewest complications.&#xD;
&#xD;
      Step 1: Patients are randomized to 1 of 6 arms:&#xD;
&#xD;
      Arm A: didanosine (ddI), stavudine (d4T), efavirenz (EFV), and nelfinavir (NFV) placebo.&#xD;
&#xD;
      Arm B: ddI, d4T, EFV placebo, and NFV. Arm C: lamivudine (3TC)/zidovudine (ZDV), EFV, and NFV&#xD;
      placebo. Arm D: 3TC/ZDV, EFV placebo, and NFV. Arm E: ddI, d4T, EFV, and NFV. Arm F: 3TC/ZDV,&#xD;
      EFV, and NFV. Patients with virologic failure on 2 successive measurements or study-drug&#xD;
      intolerance discontinue their randomized study therapy and proceed to Step 2. [AS PER&#xD;
      AMENDMENT 7/5/00: Patients must switch regimens as soon as possible after confirmation of&#xD;
      virologic failure to prevent development of drug resistance.]&#xD;
&#xD;
      Step 2:&#xD;
&#xD;
      Arm A: Patients receive treatment as in Arm D of Step 1. Arm B: Patients receive treatment as&#xD;
      in Arm C of Step 1. Arm C: Patients receive treatment as in Arm B of Step 1. Arm D: Patients&#xD;
      receive treatment as in Arm A of Step 1. Arms A, B, C, and D: Patients who fail Step 2&#xD;
      treatment proceed to Step 3. Arms E and F: Patients with virologic failure on Step 1 proceed&#xD;
      immediately to Step 3.&#xD;
&#xD;
      Step 3 (salvage therapy):&#xD;
&#xD;
      Arm A, B, C, and D: Patients receive indinavir (IDV), amprenavir (APV), ddI, and hydroxyurea&#xD;
      (HU).&#xD;
&#xD;
      [AS PER AMENDMENT 7/5/00: Patients now receive treatment on Regimen 1, 2, 3, 4, 5, or 6.&#xD;
      Regimen 1 consists of IDV, ritonavir (RTV), ddI, and HU. Regimen 2 consists of APV, RTV, ddI,&#xD;
      and HU. Regimen 3 consists of IDV, RTV, abacavir (ABC), and 3TC/ZDV. Regimen 4 consists of&#xD;
      APV, RTV, ABC, and 3TC/ZDV. Regimen 5 consists of IDV, RTV, ABC, d4T, and 3TC. Regimen 6&#xD;
      consists of APV, RTV, ABC, d4T, and 3TC.] Arm E: Patients receive IDV, APV, and 3TC/ZDV. [AS&#xD;
      PER AMENDMENT 7/5/00: Patients now receive treatment on Regimen 7 or 8. Regimen 7 consists of&#xD;
      IDV, RTV, and 3TC/ZDV. Regimen 8 consists of APV, RTV, and 3TC/ZDV.] Arm F: Patients receive&#xD;
      IDV, APV, ddI, and d4T. [AS PER AMENDMENT 7/5/00: Patients now receive treatment on Regimen 9&#xD;
      or 10. Regimen 9 consists of IDV, RTV, ddI, and d4T. Regimen 10 consists of APV, RTV, ddI,&#xD;
      and d4T.] [AS PER AMENDMENT 7/5/00: Patients already enrolled in Step 3 before site&#xD;
      registration to Version 4.0 of this protocol have the option of receiving 1 of the&#xD;
      appropriate new Step 3 regimens as outlined above or staying on their originally assigned&#xD;
      Step 3 therapy.] [AS PER AMENDMENT 3/21/01: If virologic failure on Step 1 or 2 is confirmed,&#xD;
      then HIV-1 RNA genotype resistance testing (in real-time, if possible) is performed. Patients&#xD;
      receive 1 of the Step 3 drug regimens based on the results of the resistance testing.]&#xD;
      Patients may co-enroll in metabolic, pharmacologic, immunologic, or adherence substudies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">November 2002</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>900</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indinavir sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine/Zidovudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxyurea</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abacavir sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amprenavir</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nelfinavir mesylate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stavudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Didanosine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        [Required: AS PER AMENDMENT 7/5/00:&#xD;
&#xD;
          -  Chemoprophylaxis for Pneumocystis carinii pneumonia if CD4+ cell count is less than or&#xD;
             equal to 200 cells/mm3.]&#xD;
&#xD;
        [Suggested as an alternative agent for chemoprophylaxis against Mycobacterium avium&#xD;
        complex:&#xD;
&#xD;
          -  Azithromycin.]&#xD;
&#xD;
        [Allowed: AS PER AMENDMENT 7/5/00:&#xD;
&#xD;
          -  Topical and oral antifungal agents. Oral itraconazole may be administered concurrently&#xD;
             with IDV if the dose of IDV is reduced to 600 mg every 8 hours.&#xD;
&#xD;
          -  Treatment, maintenance, or chemoprophylaxis for opportunistic infections, as&#xD;
             clinically indicated unless otherwise prohibited by the protocol.&#xD;
&#xD;
          -  All antibiotics, as clinically indicated unless otherwise prohibited by the protocol.&#xD;
&#xD;
          -  Systemic corticosteroid use for 21 days or less for acute problems, as medically&#xD;
             indicated.&#xD;
&#xD;
          -  Recombinant erythropoietin (rEPO, epoetin alfa, Epogen, epoetin beta, Marogen),&#xD;
             granulocyte colony-stimulating factor (G-CSF, filgrastim, Neupogen), and&#xD;
             granulocyte-macrophage colony-stimulating factor (GM-CSF, Regramostim).&#xD;
&#xD;
          -  Regularly prescribed medications, such as antipyretics, analgesics, allergy&#xD;
             medications, antidepressants, sleep medications, oral contraceptives, megestrol&#xD;
             acetate (Megace), testosterone, or any other medications, as medically indicated&#xD;
             unless otherwise prohibited by the protocol. NOTE: Due to the possibility that study&#xD;
             medications may alter the effectiveness of oral contraceptives or depoprogesterone,&#xD;
             these agents must not be used as the sole form of birth control, because the role of&#xD;
             some study medications on the effectiveness of these methods has not yet been&#xD;
             established.&#xD;
&#xD;
          -  Alternative therapies, such as vitamins.&#xD;
&#xD;
          -  Medications requiring low gastric pH if not administered at the same time as buffered&#xD;
             ddI. Patients taking these agents should do so at least 2 hours before ddI.]&#xD;
&#xD;
          -  Vaccinations, if administered at least 2 weeks prior to an HIV RNA viral load&#xD;
             evaluation.&#xD;
&#xD;
        [Allowed with caution: AS PER AMENDMENT 7/5/00:&#xD;
&#xD;
          -  Oral ketoconazole with IDV.&#xD;
&#xD;
        Medications that interact with PIs as substrates, inhibitors, or inducers, including, but&#xD;
        not limited to:&#xD;
&#xD;
          -  allopurinol, alprazolam, amitriptyline, atorvastatin, bupropion, carbamazepine,&#xD;
             cerivastatin, chlorpheniramine, chlorpromazine, chlorzoxazone, cimetidine,&#xD;
             clarithromycin, clofibrate, clorazepate, clozapine, codeine, dapsone, desipramine,&#xD;
             diazepam, diltiazem, disopyramide, encainide, erythromycin, estazolam, estrogens and&#xD;
             progesterones, fluoxetine, flurazepam, fluvastatin, glucocorticoids, hypericum&#xD;
             perforatum (St. John's wort), imipramine, isoniazid, itraconazole, ketoconazole,&#xD;
             labetalol, lamotrigine, lidocaine, lovastatin, mexiletine, morphine, naloxone,&#xD;
             nefazodone, nifedipine, nortriptyline, opioids, oxazepam, pentazocine, phenobarbital,&#xD;
             phenytoin, promethazine, propofol, propranolol and other beta blockers, sildenafil,&#xD;
             simvastatin, temazepam, T3 (thyroid hormone), warfarin, valproic acid, and zolpidem.&#xD;
&#xD;
          -  Drugs with high protein-binding properties, nephrotoxic drugs, and opiate agonists&#xD;
             (e.g., methadone or buprenorphine).]&#xD;
&#xD;
        NOTE:&#xD;
&#xD;
          -  Refer to package insert for potential drug interactions with IDV, RTV, NFV, or APV&#xD;
             that may require therapeutic drug monitoring and/or adjustment of concomitant&#xD;
             medications.]&#xD;
&#xD;
        [Allowed with extreme caution:&#xD;
&#xD;
          -  AS PER AMENDMENT 7/5/00:&#xD;
&#xD;
        ddI, as clinically indicated in patients with known risk factors, including, but not&#xD;
        limited to, alcohol abuse, morbid obesity, hypertriglyceridemia, cholelithiasis, endoscopic&#xD;
        retrograde cholangiopancreatography, use of medications known to cause pancreatitis (e.g.,&#xD;
        pentamidine) and use of medications known or thought to increase exposure to ddI (e.g., HU,&#xD;
        allopurinol).]&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        [Allowed:&#xD;
&#xD;
          -  AS PER AMENDMENT 7/5/00:&#xD;
&#xD;
        Acupuncture and visualization techniques.]&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV infection, as documented by any licensed ELISA test kit and confirmed by either&#xD;
             Western blot, HIV culture, HIV antigen, plasma HIV-1 RNA, or a second antibody test by&#xD;
             a method other than ELISA at any time prior to study entry.&#xD;
&#xD;
          -  Plasma HIV-1 RNA of 500 copies/ml or more, confirmed by the Roche Amplicor assay only&#xD;
             and performed within 60 days [AS PER AMENDMENT 5/5/99:&#xD;
&#xD;
          -  70 days] of study entry by any certified laboratory.&#xD;
&#xD;
          -  Inclusion laboratory parameters, documented within 14 days prior to study entry (see&#xD;
             lab values).&#xD;
&#xD;
        [AS PER AMENDMENT 9/9/99:&#xD;
&#xD;
          -  Co-enrollment on ACTG A5005s (Metabolism Substudy) is required for patients enrolling&#xD;
             under Version 3.0 of ACTG 384.]&#xD;
&#xD;
        Risk Behavior:&#xD;
&#xD;
        [Allowed with caution:&#xD;
&#xD;
          -  AS PER AMENDMENT 7/5/00:&#xD;
&#xD;
        Alcoholic beverages.]&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following condition are excluded:&#xD;
&#xD;
        AIDS-related malignancy other than minimal Kaposi's sarcoma.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        [Excluded:&#xD;
&#xD;
          -  AS PER AMENDMENT 7/5/00:&#xD;
&#xD;
          -  Chronic systemic corticosteroids.&#xD;
&#xD;
          -  For Steps 1 and 2, all antiretroviral therapies other than study medications. For step&#xD;
             3, contact the team to discuss potential addition or substitution with off-study&#xD;
             antiretroviral medications.&#xD;
&#xD;
          -  Investigational drugs without specific approval from the study chairs.&#xD;
&#xD;
          -  Neurotoxic and pancreatotoxic drugs.&#xD;
&#xD;
          -  Systemic cytotoxic chemotherapy.&#xD;
&#xD;
          -  Amiodarone, astemizole, bepridil, cisapride, cholestyramine, ergot and ergot&#xD;
             derivatives, flecainide, ganciclovir, interferon alfa, midazolam (unless used for&#xD;
             sedation on ACTG 723), pimozide, propafenone, propoxyphene, quinidine, ribavirin,&#xD;
             rifampin, sucralfate, terfenadine, and triazolam.&#xD;
&#xD;
          -  Rifabutin for patients on RTV in Step 3 and for patients on Steps 1 and 2 because of&#xD;
             the contradictory effects of EFV and NFV on plasma rifabutin levels. If a patient on&#xD;
             Step 1 or 2 requires treatment with rifabutin after coming on the study, the team must&#xD;
             be notified.&#xD;
&#xD;
          -  Alpha tocopherol (vitamin E) supplementation since vitamin E is contained in the soft&#xD;
             gelatin capsule formulation of APV.&#xD;
&#xD;
          -  ddI concurrently with IV pentamidine.&#xD;
&#xD;
          -  Herbal medications.]&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
          -  Pancreatitis within 3 years of study entry.&#xD;
&#xD;
          -  Current peripheral neuropathy grade 2 or greater or history of peripheral neuropathy&#xD;
             grade 3 or greater.&#xD;
&#xD;
          -  Documented or suspected acute hepatitis within 30 days prior to study entry.&#xD;
&#xD;
          -  Unexplained temperature above 38.5 C for any 7 days or chronic diarrhea (defined as&#xD;
             more than 3 liquid stools per day persisting for more than 15 days) within 30 days&#xD;
             prior to study entry.&#xD;
&#xD;
          -  Any previous hypersensitivity to study drugs or their components.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Receipt within 30 days of erythropoietin, G-CSF, or GM-CSF.&#xD;
&#xD;
          -  Treatment within 14 days of study entry with any of the following:&#xD;
&#xD;
          -  amiodarone, astemizole, cisapride, ergot or ergot derivatives, ketoconazole,&#xD;
             midazolam, propoxyphene, quinidine, rifampin, terfenidine, or triazolam.&#xD;
&#xD;
          -  Prior antiretroviral therapy for 7 days or more, including protease inhibitors (PIs),&#xD;
             nucleoside reverse transcriptase inhibitors (NRTIs), and nonnucleoside reverse&#xD;
             transcriptase inhibitors (NNRTIs). [AS PER AMENDMENT 5/5/99:&#xD;
&#xD;
          -  Systemic ketoconazole or itraconazole, intravenous pentamidine, and rifabutin are&#xD;
             prohibited. Midazolam is allowed for sedation in patients participating on ACTG 723.]&#xD;
&#xD;
          -  Any vaccination within 14 days prior to study entry.&#xD;
&#xD;
          -  Any immunomodulator or investigational therapy within 30 days prior to study entry.&#xD;
&#xD;
        [AS PER AMENDMENT 5/5/99:&#xD;
&#xD;
          -  6. Rifabutin is discouraged.]&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Acute therapy for an infection or other medical illness within 14 days prior to study&#xD;
             entry.&#xD;
&#xD;
        [AS PER AMENDMENT 5/5/99:&#xD;
&#xD;
          -  Acute therapy for a serious infection or other serious medical illness that is&#xD;
             potentially life-threatening and requires systemic therapy and/or hospitalization&#xD;
             within 14 days of study entry. Patients with Pneumocystis carinii pneumonia must have&#xD;
             completed acute therapy at least 7 days prior to entry and be clinically stable.&#xD;
             Patients with other serious infection or serious medical illness who must continue&#xD;
             chronic therapy must have completed at least 14 days of therapy prior to entry and be&#xD;
             clinically stable. Patients with all other infections or medical illnesses must have&#xD;
             completed therapy, or at least 14 days of maintenance therapy, prior to entry and be&#xD;
             clinically stable (restrictions do not apply to oral and vaginal candidiasis,&#xD;
             mucocutaneous herpes simplex infection, and minor skin conditions).]&#xD;
&#xD;
        Risk Behavior:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Possible current substance abuse that could prevent compliance with the study&#xD;
             medication.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Shafer</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Gregory Robbins</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Univ of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Southern California / LA County USC Med Ctr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>900331079</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA CARE Ctr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Willow Clinic</name>
      <address>
        <city>Menlo Park</city>
        <state>California</state>
        <zip>94025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of California / San Diego Treatment Ctr</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>921036325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Francisco AIDS Clinic / San Francisco Gen Hosp</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>941102859</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Francisco Gen Hosp</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>941102859</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Clara Valley Med Ctr / AIDS Community Rsch Consortium</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>951282699</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marin County Specialty Clinic</name>
      <address>
        <city>San Rafael</city>
        <state>California</state>
        <zip>94903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Mateo AIDS Program / Stanford Univ</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>943055107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Univ Med Ctr</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>943055107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor UCLA Med Ctr</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Colorado Health Sciences Ctr</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown Univ Hosp</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Howard Univ</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20059</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>331361013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Univ</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Hemo Comp Evaluation Clinic / East TN Comp Hemo Ctr</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>303652225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Hawaii</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Univ Med School</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook County Hosp</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Presbyterian - Saint Luke's Med Ctr</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Univ Hosp</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>462025250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Inf Diseases/ Indiana Univ Hosp</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Hosp of Indiana / Life Care Clinic</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Iowa Hosp and Clinic</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charity Hosp / Tulane Univ Med School</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane Med Ctr Hosp</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane Univ School of Medicine</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State of MD Div of Corrections / Johns Hopkins Univ Hosp</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>212052196</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harvard (Massachusetts Gen Hosp)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Med Ctr</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess - West Campus</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Louis Regional Hosp / St Louis Regional Med Ctr</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Nebraska Med Ctr</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>681985130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY / Erie County Med Ctr at Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manhattan Veterans Administration / New York Univ Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chelsea Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell Univ Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mem Sloan - Kettering Cancer Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Presbyterian Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Mary's Hosp (Univ of Rochester/Infectious Diseases)</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>275997215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Med Ctr</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Univ Med Ctr</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moses H Cone Memorial Hosp</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akron City Hospital</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>452670405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Kentucky Lexington</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve Univ</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroHealth Med Ctr</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>441091998</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State Univ Hosp Clinic</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>432101228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milton S Hershey Med Ctr</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>170330850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philadelphia Veterans Administration Med Ctr</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Pennsylvania at Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Pittsburgh Med Ctr</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Julio Arroyo</name>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <zip>29169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Texas Galveston</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>775550435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Umberto I</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S Orsola</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spedali Civili - Carosi</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spedali Civili Cadeo</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Archispedale S Anna</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita di Genova</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Luigi Cacco Moroni</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Luigi Sacco Cargnel</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Parma</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico S Matteo Filice</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico S Matteo Minoli</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Archispedale S Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita di Roma - Delia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Maggiore</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Puerto Rico</name>
      <address>
        <city>San Juan</city>
        <zip>009365067</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda USL di Piacenza</name>
    </facility>
  </location>
  <location>
    <facility>
      <name>Francesco Leoncini</name>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Smeaton LM, DeGruttola V, Robbins GK, Shafer RW. ACTG (AIDS Clinical Trials Group) 384: a strategy trial comparing consecutive treatments for HIV-1. Control Clin Trials. 2001 Apr;22(2):142-59. doi: 10.1016/s0197-2456(00)00126-4.</citation>
    <PMID>11306153</PMID>
  </reference>
  <reference>
    <citation>Dube MP, Zackin R, Tebas P, et al. Prospective study of regional body composition in antiretroviral-naive subjects randomized to receive zidovudine+lamivudine or didanosine+stavudine combined with nelfinavir, efavirenz, or both: A5005s, a substudy of ACTG 384. Antiviral Ther. 2002;7:L18. Abstract 27.</citation>
  </reference>
  <reference>
    <citation>Smith PF, Robbins G, Shafer R, Wu H, Yu S, Hirsch M, Merigan T, Morse GD, ACTG 384 Study Team. Effect of Efavirenz on the Pharmacokinetics of Nelfinavir and M8 in Na√Øve, HIV-infected Patients Receiving Long-term HAART Therapy. 10th Conference on Retroviruses and Oppurtunistic Infections. Feb 2003. Abstract 148.</citation>
  </reference>
  <results_reference>
    <citation>Shafer RW, Smeaton LM, Robbins GK, De Gruttola V, Snyder SW, D'Aquila RT, Johnson VA, Morse GD, Nokta MA, Martinez AI, Gripshover BM, Kaul P, Haubrich R, Swingle M, McCarty SD, Vella S, Hirsch MS, Merigan TC; AIDS Clinical Trials Group 384 Team. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003 Dec 11;349(24):2304-15. doi: 10.1056/NEJMoa030265.</citation>
    <PMID>14668456</PMID>
  </results_reference>
  <results_reference>
    <citation>Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, Pettinelli C, Dube MP, Fischl MA, Pollard RB, Delapenha R, Gedeon L, van der Horst C, Murphy RL, Becker MI, D'Aquila RT, Vella S, Merigan TC, Hirsch MS; AIDS Clinical Trials Group 384 Team. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003 Dec 11;349(24):2293-303. doi: 10.1056/NEJMoa030264.</citation>
    <PMID>14668455</PMID>
  </results_reference>
  <results_reference>
    <citation>Reynolds NR, Testa MA, Marc LG, Chesney MA, Neidig JL, Smith SR, Vella S, Robbins GK; Protocol Teams of ACTG 384, ACTG 731 and A5031s. Factors influencing medication adherence beliefs and self-efficacy in persons naive to antiretroviral therapy: a multicenter, cross-sectional study. AIDS Behav. 2004 Jun;8(2):141-50. doi: 10.1023/B:AIBE.0000030245.52406.bb.</citation>
    <PMID>15187476</PMID>
  </results_reference>
  <results_reference>
    <citation>Hulgan T, Haas DW, Haines JL, Ritchie MD, Robbins GK, Shafer RW, Clifford DB, Kallianpur AR, Summar M, Canter JA. Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study. AIDS. 2005 Sep 2;19(13):1341-9. doi: 10.1097/01.aids.0000180786.02930.a1.</citation>
    <PMID>16103764</PMID>
  </results_reference>
  <results_reference>
    <citation>Smith PF, Robbins GK, Shafer RW, Wu H, Yu S, Hirsch MS, Merigan TC, Park JG, Forrest A, Fischl MA, Morse GD; ACTG 384-5006 Team. Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2005 Aug;49(8):3558-61. doi: 10.1128/AAC.49.8.3558-3561.2005.</citation>
    <PMID>16048984</PMID>
  </results_reference>
  <results_reference>
    <citation>Haas DW, Smeaton LM, Shafer RW, Robbins GK, Morse GD, Labbe L, Wilkinson GR, Clifford DB, D'Aquila RT, De Gruttola V, Pollard RB, Merigan TC, Hirsch MS, George AL Jr, Donahue JP, Kim RB. Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis. 2005 Dec 1;192(11):1931-42. doi: 10.1086/497610. Epub 2005 Nov 1.</citation>
    <PMID>16267764</PMID>
  </results_reference>
  <results_reference>
    <citation>Gandhi RT, Spritzler J, Chan E, Asmuth DM, Rodriguez B, Merigan TC, Hirsch MS, Shafer RW, Robbins GK, Pollard RB; ACTG 384 Team. Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384. J Acquir Immune Defic Syndr. 2006 Aug 1;42(4):426-34. doi: 10.1097/01.qai.0000226789.51992.3f.</citation>
    <PMID>16810109</PMID>
  </results_reference>
  <results_reference>
    <citation>Marc LG, Testa MA, Walker AM, Robbins GK, Shafer RW, Anderson NB, Berkman LF; ACTG Data Analysis Concept Sheet Study Team. Educational attainment and response to HAART during initial therapy for HIV-1 infection. J Psychosom Res. 2007 Aug;63(2):207-16. doi: 10.1016/j.jpsychores.2007.04.009.</citation>
    <PMID>17662759</PMID>
  </results_reference>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 5, 2012</last_update_submitted>
  <last_update_submitted_qc>June 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV Protease Inhibitors</keyword>
  <keyword>Reverse Transcriptase Inhibitors</keyword>
  <keyword>Anti-HIV Agents</keyword>
  <keyword>Viral Load</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Nelfinavir</mesh_term>
    <mesh_term>Indinavir</mesh_term>
    <mesh_term>Amprenavir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Abacavir</mesh_term>
    <mesh_term>Didanosine</mesh_term>
    <mesh_term>Stavudine</mesh_term>
    <mesh_term>Lamivudine, zidovudine drug combination</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Hydroxyurea</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

